Pregnancy Medication Restrictions and PI Treatment Disruption

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

When a personal injury plaintiff becomes pregnant during litigation, or is pregnant at the time of the accident, virtually every medication in the treatment plan must be re-evaluated for fetal safety. The resulting treatment disruption — discontinued medications, substituted alternatives, and untreated conditions — is a foreseeable consequence of the injury that creates unique damages documentation opportunities.

Pregnancy Medication Restrictions and PI Treatment Disruption

When a personal injury plaintiff who is pregnant or becomes pregnant during litigation requires medication for accident-related injuries, the treatment plan enters a clinically complex zone where most standard PI medications are restricted or contraindicated. NSAIDs are contraindicated after 20 weeks gestation. Most muscle relaxants lack adequate pregnancy safety data. Many anticonvulsants used for neuropathic pain carry teratogenic risk. The treatment disruption caused by pregnancy-related medication restrictions is a foreseeable consequence of the original injury that creates documentable damages — and PI attorneys must understand these restrictions to properly value the case.

• Pregnancy contraindicates or restricts the majority of medications commonly prescribed in PI treatment plans
• Treatment disruption from medication discontinuation during pregnancy is a foreseeable consequence of the original injury
• The plaintiff's untreated or undertreated pain during pregnancy constitutes a separate damages element
• Post-delivery medication reintroduction often requires starting the treatment plan over, extending the case timeline
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, pregnancy-related medication restrictions create a treatment gap that is clinically necessary but that the defendant's negligence made necessary in the first place

FDA Pregnancy Categories and What They Mean

The FDA replaced its traditional letter-grade pregnancy categories (A, B, C, D, X) with the Pregnancy and Lactation Labeling Rule (PLLR) in 2015, requiring narrative descriptions of pregnancy risk. However, the practical effect for PI treatment remains the same: most medications used in personal injury care carry significant pregnancy-related restrictions.

Contraindicated medications include NSAIDs (ibuprofen, naproxen, celecoxib) after 20 weeks gestation due to fetal renal and cardiovascular risks; many anticonvulsants (valproic acid, topiramate) due to teratogenic risk; ACE inhibitors and ARBs; certain migraine medications including ergotamines; and isotretinoin.

Restricted-use medications include opioids (associated with neonatal abstinence syndrome with prolonged use), certain SSRIs and SNRIs (requiring risk-benefit analysis), and gabapentin (limited human data but animal teratogenicity concerns).

Relatively safer alternatives are limited and often less effective. Acetaminophen is generally considered acceptable but provides limited pain control for injury-related conditions. Physical therapy modalities may replace some medications but cannot address all symptoms.

The Treatment Disruption Pattern

When a plaintiff becomes pregnant during PI treatment, the following disruption pattern typically occurs:

Phase 1: Medication discontinuation. The prescriber must stop or taper multiple medications that are unsafe during pregnancy. For a plaintiff on gabapentin, an NSAID, a muscle relaxant, and a sleep aid, this may mean discontinuing three or four medications simultaneously.

Phase 2: Inadequate substitution. The prescriber attempts to manage the accident-related conditions with pregnancy-safe alternatives, which are fewer and generally less effective. Pain control deteriorates. Muscle spasm management is limited. Sleep disruption worsens.

Phase 3: Untreated or undertreated symptoms. For the duration of the pregnancy, the plaintiff endures accident-related symptoms with suboptimal treatment. This period of suffering is directly attributable to the medication restrictions necessitated by the combination of the accident injuries and the pregnancy.

Phase 4: Post-delivery reintroduction. After delivery (and potentially after breastfeeding cessation, which may extend the restriction period by months or years), the prescriber must reintroduce the original medications. This often requires re-titration, re-assessment, and potentially different medication selections if the plaintiff's condition has changed during the untreated period.

Damages Implications

Extended treatment timeline. The pregnancy creates a mandatory treatment gap that extends the total case timeline by the duration of the pregnancy plus any breastfeeding period. A case that might have resolved in 18 months may extend to 30 months or longer.

Increased pain and suffering. The period of inadequate treatment during pregnancy is a discrete damages element. The plaintiff is experiencing pain that could have been managed with medications but cannot be due to pregnancy safety concerns — pain that would not exist but for the defendant's negligence.

Treatment restart costs. Re-titrating medications after delivery incurs additional physician visits, pharmacy dispensing, and monitoring costs. The plaintiff essentially restarts the medication management process, generating additional medical expenses.

Potential condition deterioration. Untreated or undertreated pain conditions may worsen during the medication gap. Chronic pain that was being managed effectively may progress or become more refractory when medications are eventually reintroduced, requiring more aggressive treatment.

Documentation Strategy

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For cases involving pregnancy-related medication restrictions, the MERIT documentation captures:

• The pre-pregnancy medication regimen and its clinical justification
• Each medication that was discontinued or modified due to pregnancy
• The pregnancy-safe alternatives attempted and their limitations
• The post-delivery medication reintroduction timeline

This documentation creates a clear narrative of treatment disruption caused by the intersection of pregnancy and accident-related injuries. For additional context on how medication discontinuation and rechallenge patterns serve as evidence, see Medication Discontinuation and Rechallenge Evidence.

For more on how treatment timeline disruptions affect the overall damages narrative, see Prescription Timing and Accident Date Causation Evidence.

Practical Takeaway

When a PI plaintiff is pregnant or becomes pregnant during litigation, the attorney should immediately coordinate with treating physicians and pharmacists to document the medication restrictions, the resulting treatment gaps, and the plaintiff's experience during the period of inadequate treatment. This documentation transforms a clinical complication into a clearly articulated damages element that the defense cannot dispute.

Contact LienScripts to discuss how pharmacist review supports medication management during pregnancy-complicated PI cases.